Krishnan Suma sold $9.0M of KRYS
Krishnan Suma (President, R&D) sold 25,000 shares of Krystal Biotech, Inc. (KRYS) at an average of $359.32 ($354.54–$366.56, $8.98M total) across 13 trades on 2026-09-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed $9M sale may trigger short‑term price pressure but does not alter the company's underlying pipeline.
Market read
Insider sell of this size is noteworthy for a micro‑cap biotech and could influence short‑term trading.
What to watch
Potential upcoming clinical data releases or financing events that could offset sell pressure.
Background
Form 4 filing discloses insider transactions required by the SEC.
Ticker impact
President of R&D sold 25,000 shares for $9M via a 10b5-1 plan on 2026-09-04.
Potential short-term downside as market digests the $9M sale.
The sale represents a significant dollar amount for a micro‑cap biotech and was executed through a pre‑arranged plan, suggesting possible insider expectations of near‑term weakness.
Market effects
May raise concerns for other small‑cap biotech stocks about insider sentiment.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact; primarily relevant to KRYS shareholders.
Counterpoint
The sale could be purely liquidity‑driven and not reflect fundamentals.
Key entities
- companyKrystal Biotech, Inc.
Biotech firm listed on Nasdaq under KRYS.
- insiderKrishnan Suma
President of R&D, officer and 10% owner.
